ABUS vs ICE · P/E 5.4, rev $6.2M vs P/E 37, rev $12.64B
Arbutus Biopharma Corp (ABUS) versus Intercontinental Exchange Inc (ICE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Intercontinental Exchange Inc (ICE) is a financial data & stock exchanges company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported ICE revenue for 2025-12-31 was $12.64B. Net income was $3.31B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. ICE currently screens at market cap $103.55B and trailing P/E 37.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. ICE currently screens at market cap $103.55B and trailing P/E 37.3.
Not investment advice. Open the ABUS and ICE stock pages for the full models.
Not investment advice.